Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | N/A |
| 52 Week High | $16.98 |
| 52 Week Low | $4.25 |
| Target Price | $19.00 |
| Ticker | VECT:UW |
| Composite Ticker | VECT:US |
| Security Name | VectivBio Holding AG |
| Type | Ordinary Shares |
| Class | VECT |
| Currency | USD |
| Round Lot Size | N/A |
| Primary | Yes |
| Delisted | Yes |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG00ZR8HC19 |
| Composite FIGI | BBG00ZR8HBH4 |
| Share Class FIGI | BBG00ZR8HCJ0 |
| FIGI Unique ID | EQ0000000089439167 |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | N/A |
| Beta | -0.1542 |
| 1-year beta | 0.0627 |
| 3-year beta | -0.1542 |
| 5-year beta | -0.1542 |
| 7-year beta | -0.1542 |
| 10-year beta | -0.1542 |
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
